NIH-Backed US Study Of Mixed COVID-19 Vaccines Regime To Conclude Soon: CNBC - AstraZeneca (NASDAQ:AZN), Johnson & Johnson (NYSE:JNJ), Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE)

The National Institutes of Health (NIH) is close to concluding trials evaluating mix n match COVID-19 vaccines regime, reports CNBC.
Related: US NIH Initiates Trial to Assess Mix-Match of COVID-19 Vaccine Booster Shots.
White House chief medical advisor, Dr. Anthony Fauci, said that safety and efficacy data on pairing a primary COVID-19 shot from one manufacturer with boosters from another could be available within the next two weeks.
The NIH is close to completing trials that mixed boosters and initial doses from Pfizer Inc PFE, Moderna Inc MRNA, and Johnson & Johnson JNJ, Fauci said at a White House Covid briefing.
Though the Centers for Disease Control and Prevention authorized Pfizer’s booster for seniors and the medically vulnerable.
Data on Johnson & Johnson’s mix-and-match study could be ready within a week, while Pfizer’s trial might be completed by mid-October.
Moderna’s mix-and-match study data is already available, Fauci added.
Related: UK Study Of COVID-19 Shots Mix-Match Shows Immune Response, Can Add Flexibility To Vaccination Programs.
In May, interim data from the U.K. trial evaluating mixture of Oxford-AstraZeneca Plc AZN vaccine and Pfizer - BioNTech SE BNTX showed some short-lived side effects.
Related Link: UK Study Answers Question If Two Doses Of COVID-19 Vaccines Can Be Mix-Matched?
In July, the EU regulator also said to weigh mix-and-match booster COVID-19 shots.
Related: EU Regulator Weighing Mix-And-Match, Boosters For COVID-19 Shots.
Most recently, the U.K. also said that it is preparing for a mixed COVID-19 booster program.
Also Read: UK Preps Up For ‘Mix & Match’ COVID-19 Booster Program.
Photo by Johaehn from Pixabay

Market News and Data brought to you by Benzinga APIs